This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2001 Dec 19;93(24):1830-2.

doi: 10.1093/jnci/93.24.1830.

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect

J Albanell, J Baselga

PMID: 11752000
DOI: 10.1093/jnci/93.24.1830

Editorial

Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect

J Albanell et al. J Natl Cancer Inst. 2001.

. 2001 Dec 19;93(24):1830-2.

doi: 10.1093/jnci/93.24.1830.

Authors

J Albanell, J Baselga

PMID: 11752000
DOI: 10.1093/jnci/93.24.1830

No abstract available

PubMed Disclaimer

Comment on

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Lu Y, et al. J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. doi: 10.1093/jnci/93.24.1852. J Natl Cancer Inst. 2001. PMID: 11752009

Similar articles

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y, Zi X, Pollak M. Lu Y, et al. Int J Cancer. 2004 Jan 20;108(3):334-41. doi: 10.1002/ijc.11445. Int J Cancer. 2004. PMID: 14648698
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Lu Y, et al. J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. doi: 10.1093/jnci/93.24.1852. J Natl Cancer Inst. 2001. PMID: 11752009
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.
Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B. Huang X, et al. Cancer Res. 2010 Feb 1;70(3):1204-14. doi: 10.1158/0008-5472.CAN-09-3321. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103628
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Nahta R, et al. Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509. Nat Clin Pract Oncol. 2006. PMID: 16683005 Review.
Mechanism of action of trastuzumab and scientific update.
Baselga J, Albanell J, Molina MA, Arribas J. Baselga J, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11. doi: 10.1016/s0093-7754(01)90276-3. Semin Oncol. 2001. PMID: 11706390 Review.

See all similar articles

Cited by

Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.
Mukherjee A, Badal Y, Nguyen XT, Miller J, Chenna A, Tahir H, Newton A, Parry G, Williams S. Mukherjee A, et al. PLoS One. 2011 Jan 28;6(1):e16443. doi: 10.1371/journal.pone.0016443. PLoS One. 2011. PMID: 21297994 Free PMC article.
Therapeutic destruction of insulin receptor substrates for cancer treatment.
Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A. Reuveni H, et al. Cancer Res. 2013 Jul 15;73(14):4383-94. doi: 10.1158/0008-5472.CAN-12-3385. Epub 2013 May 7. Cancer Res. 2013. PMID: 23651636 Free PMC article.
Involvement of insulin receptor substrate 2 in mammary tumor metastasis.
Nagle JA, Ma Z, Byrne MA, White MF, Shaw LM. Nagle JA, et al. Mol Cell Biol. 2004 Nov;24(22):9726-35. doi: 10.1128/MCB.24.22.9726-9735.2004. Mol Cell Biol. 2004. PMID: 15509777 Free PMC article.
Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.
Keating GM. Keating GM. Drugs. 2012 Feb 12;72(3):353-60. doi: 10.2165/11209000-000000000-00000. Drugs. 2012. PMID: 22316351 Review.
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, Tsukuda K, Ogasawara Y, Shimizu N. Fujita T, et al. Br J Cancer. 2006 Jan 30;94(2):247-52. doi: 10.1038/sj.bjc.6602926. Br J Cancer. 2006. PMID: 16404430 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database